373 related articles for article (PubMed ID: 26001898)
1. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics approaches.
Gani OA; Thakkar B; Narayanan D; Alam KA; Kyomuhendo P; Rothweiler U; Tello-Franco V; Engh RA
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1605-16. PubMed ID: 26001898
[TBL] [Abstract][Full Text] [Related]
2. Perspective on computational and structural aspects of kinase discovery from IPK2014.
Martin E; Knapp S; Engh RA; Moebitz H; Varin T; Roux B; Meiler J; Berdini V; Baumann A; Vieth M
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1595-604. PubMed ID: 25861861
[TBL] [Abstract][Full Text] [Related]
3. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
Modugno M; Casale E; Soncini C; Rosettani P; Colombo R; Lupi R; Rusconi L; Fancelli D; Carpinelli P; Cameron AD; Isacchi A; Moll J
Cancer Res; 2007 Sep; 67(17):7987-90. PubMed ID: 17804707
[TBL] [Abstract][Full Text] [Related]
5. Integrating ligand-based and protein-centric virtual screening of kinase inhibitors using ensembles of multiple protein kinase genes and conformations.
Dixit A; Verkhivker GM
J Chem Inf Model; 2012 Oct; 52(10):2501-15. PubMed ID: 22992037
[TBL] [Abstract][Full Text] [Related]
6. Crystallography for protein kinase drug design: PKA and SRC case studies.
Breitenlechner CB; Bossemeyer D; Engh RA
Biochim Biophys Acta; 2005 Dec; 1754(1-2):38-49. PubMed ID: 16269279
[TBL] [Abstract][Full Text] [Related]
7. Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery.
Volkamer A; Eid S; Turk S; Jaeger S; Rippmann F; Fulle S
J Chem Inf Model; 2015 Mar; 55(3):538-49. PubMed ID: 25557645
[TBL] [Abstract][Full Text] [Related]
8. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
9. Understanding kinase selectivity through energetic analysis of binding site waters.
Robinson DD; Sherman W; Farid R
ChemMedChem; 2010 Apr; 5(4):618-27. PubMed ID: 20183853
[TBL] [Abstract][Full Text] [Related]
10. Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries.
Moret N; Clark NA; Hafner M; Wang Y; Lounkine E; Medvedovic M; Wang J; Gray N; Jenkins J; Sorger PK
Cell Chem Biol; 2019 May; 26(5):765-777.e3. PubMed ID: 30956147
[TBL] [Abstract][Full Text] [Related]
11. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.
Dar AC; Shokat KM
Annu Rev Biochem; 2011; 80():769-95. PubMed ID: 21548788
[TBL] [Abstract][Full Text] [Related]
12. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors.
Hantschel O
ACS Chem Biol; 2015 Jan; 10(1):234-45. PubMed ID: 25531586
[TBL] [Abstract][Full Text] [Related]
13. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.
Ung PM; Schlessinger A
ACS Chem Biol; 2015 Jan; 10(1):269-78. PubMed ID: 25420233
[TBL] [Abstract][Full Text] [Related]
14. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
Verkhivker GM
Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
[TBL] [Abstract][Full Text] [Related]
15. Fragment-based approaches to the discovery of kinase inhibitors.
Mortenson PN; Berdini V; O'Reilly M
Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
[TBL] [Abstract][Full Text] [Related]
16. Transplant-insert-constrain-relax-assemble (TICRA): protein-ligand complex structure modeling and application to kinases.
Meshkat S; Klon AE; Zou J; Wiseman JS; Konteatis Z
J Chem Inf Model; 2011 Jan; 51(1):52-60. PubMed ID: 21117680
[TBL] [Abstract][Full Text] [Related]
17. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the predictivity of virtual screening for ABL kinase inhibitors to hinder drug resistance.
Gani OA; Narayanan D; Engh RA
Chem Biol Drug Des; 2013 Nov; 82(5):506-19. PubMed ID: 23746052
[TBL] [Abstract][Full Text] [Related]
19. A small molecule discrimination map of the antibiotic resistance kinome.
Shakya T; Stogios PJ; Waglechner N; Evdokimova E; Ejim L; Blanchard JE; McArthur AG; Savchenko A; Wright GD
Chem Biol; 2011 Dec; 18(12):1591-601. PubMed ID: 22195561
[TBL] [Abstract][Full Text] [Related]
20. Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome.
Martin E; Mukherjee P
J Chem Inf Model; 2012 Jan; 52(1):156-70. PubMed ID: 22133092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
